- $82.31m
- $15.47m
- $13.86m
Annual balance sheet for Pyxis Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 275 | 179 | 119 | 127 | 66.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 0.598 | 0.021 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 279 | 187 | 125 | 132 | 72.1 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.24 | 24.8 | 24.8 | 22.1 | 19.4 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 280 | 211 | 174 | 157 | 91.5 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.7 | 31.6 | 25.8 | 17.7 | 21.1 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 18.7 | 50.6 | 48 | 36.4 | 38.1 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 261 | 161 | 126 | 121 | 53.4 |
| Total Liabilities & Shareholders' Equity | 280 | 211 | 174 | 157 | 91.5 |
| Total Common Shares Outstanding |